Bolt Biotherapeutics, Inc. (BOLT) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 3 Buy, 5 Hold.
The consensus price target is $7.00, representing an upside of 50.2% from the current price $4.66.
Analysts estimate Earnings Per Share (EPS) of $-32.27 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.65 vs est $-32.27 (beat +94.9%). 2025: actual $-17.85 vs est $-21.23 (beat +15.9%). Analyst accuracy: 0%.
BOLT Stock — 12-Month Price Forecast
$7.00
▲ +50.21% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Bolt Biotherapeutics, Inc., the price target is $7.00.
The average price target represents a +50.21% change from the last price of $4.66.
BOLT Analyst Ratings
Hold
Based on 8 analysts giving stock ratings to Bolt Biotherapeutics, Inc. in the past 3 months
EPS Estimates — BOLT
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.65
vs Est –$32.27
▲ 1,855.6% off
2025
Actual –$17.85
vs Est –$21.23
▲ 18.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BOLT
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.008B
vs Est $0.008B
▼ 10.2% off
2025
Actual $0.008B
vs Est $0.006B
▲ 23.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
